Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Lonza Group    LONN   CH0013841017

LONZA GROUP

(LONN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
03/30/2020 03/31/2020 04/01/2020 04/02/2020 04/03/2020 Date
393.8(c) 402.2(c) 395.4(c) 391.3(c) 401.7(c) Last
425 705 497 170 459 281 405 530 403 624 Volume
+3.14% +2.13% -1.69% -1.04% +2.66% Change
More quotes
Financials (CHF)
Sales 2020 6 215 M
EBIT 2020 1 259 M
Net income 2020 811 M
Debt 2020 2 844 M
Yield 2020 0,75%
Sales 2021 6 661 M
EBIT 2021 1 455 M
Net income 2021 958 M
Debt 2021 2 251 M
Yield 2021 0,81%
P/E ratio 2020 35,8x
P/E ratio 2021 30,3x
EV / Sales2020 5,13x
EV / Sales2021 4,70x
Capitalization 29 069 M
More Financials
Company
Lonza Group is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows: - bio-pharmaceuticals and nutritional ingredients (70.4%): exclusive syntheses, microbiological fermentation products ,... 
Sector
Biotechnology & Medical Research
Calendar
04/28 | 04:00amShareholder meeting
More about the company
Surperformance© ratings of Lonza Group
Trading Rating : Investor Rating :
More Ratings
Latest news on LONZA GROUP
03/24LONZA : Launches New TheraPEAK SfAAV Medium to Boost and Optimize the Production..
AQ
03/23LONZA : Publishes 2020 AGM Invitation
AQ
03/23LONZA : Joins the MIT Industrial Liason Program
AQ
03/18LONZA : Publishes its Online Annual and Sustainability Reports 2019
AQ
03/12LONZA : Strengthens its Executive Committee with the Appointment of New CHRO
AQ
03/11LONZA GROUP : Nomination
CO
03/10LONZA : Collaborates with Immunotherapy Leaders to Assess Point-of-Care Manufact..
AQ
02/24LONZA : France's Sanofi to carve out active drug ingredients business
RE
02/24LONZA : Connects Science and Nature with Responsibly Made Capsules and Formulati..
AQ
02/20LONZA : confirms COVID-19 case at Singapore General Office
AQ
02/11LONZA : invests CHF 12 million to reduce greenhouse gas emissions in Visp
AQ
02/05GENERAL ANNOUNCEMENT : :Sale of Lonza Shares by a Member of the Executive Commit..
PU
02/02GENERAL ANNOUNCEMENT : :Notice of Book Closure Date for Share Premium Dividend
PU
01/31LONZA : Chairman statement regarding 19 January 2020 accident at Visp site
AQ
01/29ROCKET PHARMACEUTICALS : Lonza Supporting Rocket Pharma with Clinical Manufactur..
AQ
More news
News in other languages on LONZA GROUP
06:33aEMPRUNT : Lonza lève 300 millions de francs à 1,0%, échéance 2023
05:52aANLEIHE : Lonza begibt 300 Millionen Franken zu 1,0% bis 2023
03/20Lonza tiendra son assemblée générale en cercle restreint
03/20Lonza hält GV ohne physische Präsenz der Aktionäre ab
03/17L'ancien patron de Lonza mieux payé l'an dernier que son successeur
More news
Chart LONZA GROUP
Duration : Period :
Lonza Group Technical Analysis Chart | LONN | CH0013841017 | MarketScreener
Technical analysis trends LONZA GROUP
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 407,88  CHF
Last Close Price 391,30  CHF
Spread / Highest target 31,8%
Spread / Average Target 4,24%
Spread / Lowest Target -29,7%
EPS Revisions
Managers
NameTitle
Albert M. Baehny Chairman & Chief Executive Officer
Rodolfo Savitzky Chief Financial Officer
Patrick Aebischer Vice Chairman
Margot A. Scheltema Independent Director
Werner J. Bauer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
LONZA GROUP10.79%31 009
CELLTRION, INC.22.13%25 160
IQVIA HOLDINGS INC.-32.19%20 797
SEATTLE GENETICS, INC.3.86%19 875
INCYTE CORPORATION-15.05%15 874
GALAPAGOS-6.43%12 893